At least five out of 12 types of cancer examined including breast invasive carcinoma (BRCA), kidney renal papillary cell carcinoma (KIRP), liver hepatocellular carcinoma (LIHC), lung squamous cell carcinoma (LUSC) and LUAD show significant down-regulation of FCN3 in tumor tissues (Supplementary Fig. 1A). This evidence concerns the gene FCN3 and cancer.